San Francisco, 3
October 2018: The antibiotics market is
expected to reach USD 57.0 billion by 2024, according to the new report by
Grand View Research, Inc. Rising prevalence of infectious diseases especially
in developing regions such as Asia Pacific and MEA is anticipated to contribute
towards market growth.
More than 15.0% of the
deaths, in children below the age of five, are estimated to be due to pneumonia
and according to the statistics provided by the WHO about 9.2 million deaths
were recorded in 2015. Similar to tuberculosis, the highest prevalence of the
disease is identified to be in the South Asian and Sub-Saharan regions. Currently,
the required antibiotic treatment is available only to one third of the
infected population, thereby increasing the disease burden.
Government reforms
specific to antibiotics such as the Generating Antibiotics Incentives Now
(GAIN) Act in the U.S. are projected to help market growth over the forecast
period. This further expected facilitate development of advanced drugs.
On the contrary,
uncertain regulatory policies are likely to hinder the growth of this vertical
impacting market growth significantly. In 2013, the U.S. FDA revised the
guidance for registration trials for drugs used in the treatment of acute
bacterial skin and skin structure infections. The guidance states the use of
short term measures of anti-infective efficacy (percent reduction in lesion
size at 48 to 72 hours) as opposed to long term measures such as resolution of
infection at 10-14 days, which is termed as Test to Cure or TOC.
Access Research Report
of Antibiotics Market@ www.grandviewresearch.com/industry-analysis/antibiotic-market
Further Key Findings From the Study Suggest:
· Antibiotic segment including tetracyclines,
imidazoles, lincosamides and monoclonal antibodies held commanding share in
2015 and are also anticipated to grow at a lucrative growth rate over the
forecast period
· Development of monoclonal antibodies for
antibiotic resistant microorganism is key highlight of this segment. Increasing
incidences of pneumonia, blood stream infections, and urinary tract infections
(UTI) are anticipated to foster the usage of carbapenems class of antibiotics.
· Cell wall synthesis inhibitors dominated
the mechanism outlook in 2015. Majority of the antibiotics such as penicillins,
cephalosporins and carbapenems forms the cell wall synthesis inhibitor class.
· RNA synthesis inhibitors as well as folic
acid synthesis inhibitors are anticipated to witness healthy growth over the
forecast period. Development of several antiviral drugs which inhibit
transcription and reverse transcription process are anticipated to support the
growth. Folic acid inhibitor sulfa drugs are anticipated to grow as they have
wide application scope.
· Asia Pacific on account of huge population
base, high prevalence of infectious diseases, regulation reforms and greater
usage of generic medicine held commanding share in 2015.
· Latin America, especially Brazil with
strong growth in pharmaceutical sector is also projected to exhibit
remunerative growth. Outbreak of certain viruses such as Ebola in African
region also contributed towards the significant growth of MEA region.
· Some of the key players in this vertical
are Pfizer, Inc., Janssen Pharmaceuticals, Abbott, GlaxoSmithKline plc, Sanofi,
Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company and
Astellas Pharma, Inc.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the antibiotics market on the basis of drug class and region:
Global Antibiotics Drug Class Outlook (Revenue, USD
Million, 2013 - 2024)
·
Cephalosporins
·
Penicillins
·
Fluoroquinolones
·
Macrolides
·
Carbapenems
·
Aminoglycosides
·
Sulfonamides
·
Other
Global Mechanism Outlook (Revenue, USD Million, 2013 -
2024)
·
Cell Wall Synthesis Inhibitors
·
Protein Synthesis Inhibitors
·
DNA Synthesis Inhibitors
·
RNA Synthesis Inhibitors
·
Mycolic Acid Inhibitors
Antibiotics Regional Outlook (Revenue, USD Million, 2013
- 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
o
India
·
Latin America
o
Brazil
o
Mexico
·
MEA
o South Africa
Access Press Release of
Antibiotics Market@ www.grandviewresearch.com/press-release/global-antibiotic-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business decisions,
we offer market intelligence studies ensuring relevant and fact-based research
across a range of industries, from technology to chemicals, materials and
healthcare.
No comments:
Post a Comment